The identification of mitochondrial disease-specific markers (EFHD1, SASH1, FAM110B, and SLC25A18) highlights shared mechanisms, such as oxidative phosphorylation, calcium signaling, and immune responses, that can serve as therapeutic targets in both AD and GBM. Here, SLC25A18 is linked to mitochondrial disease.